Biotin interferences: Have we neglected the impact on serological markers?
(2020) Clinica Chimica Acta — Vol. 503, p. 107-112 (2020)
Files
BayartJLClinChimActa2020.pdf
Open Access - Adobe PDF
- 499.34 KB
Details
- Authors
- Abstract
- (en) BACKGROUND: Biotin has been reported to be a leading cause of interference on several immunoassay platforms using the streptavidin-biotin immobilization system. While biotin interferences have now been well characterized for several assays, only few data are available on their impact on serological markers of infectious viral diseases. METHODS: Overall, 10 healthy volunteers (HVs) received a single 100 mg dose of biotin to evaluate its effect on hepatitis B serological markers. Blood samples were taken several times before and after biotin intake. In addition, spiking experiments were applied to investigate biotin's impact on anti-HIV/p24 Ag and anti-HCV antibody levels. Several procedures designed to overcome this interference were evaluated. RESULTS: Biotin intake resulted in a false-negative anti-HBs immunological status (<10 mIU/mL) in 40.0% of cases. According to our anti-HBc and anti-HBe results, biotin intake was associated with 90.0% and 80.0% of false positive results, respectively. At the theoretical biotin peak concentration following a 100 mg intake, 50.0% and 66.6% of anti-HIV and anti-HCV results were false negatives, respectively. All the procedures evaluated to overcome the interference were proven effective. CONCLUSION: HBV, HCV, and HIV serological markers are likely to be highly sensitive to biotin. Our data confirm that the scope of biotin interference is broader than commonly described.
- Affiliations
Citations
Bayart, J.-L., Favresse, J., Stoefs, A., Closset, M., Roy, T., Fillee, C., Rodriguez-Villalobos, H., Kabamba-Mukadi, B., & Gruson, D. (2020). Biotin interferences: Have we neglected the impact on serological markers? Clinica Chimica Acta, 503, 107-112. https://doi.org/10.1016/j.cca.2020.01.012 (Original work published 2020)